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Abstract
Background: A certain number of mutations in the Microtubule-Associated Protein Tau (MAPT) gene have been
identified in individuals with high risk to develop neurodegenerative diseases, collectively called tauopathies. The
mutation A152TMAPT was recently identified in patients diagnosed with frontotemporal spectrum disorders,
including Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD),
and Alzheimer disease (AD). The A152TMAPT mutation is unusual since it lies within the N-terminal region of Tau
protein, far outside the repeat domain that is responsible for physiological Tau-microtubule interactions and
pathological Tau aggregation. How A152TMAPT causes neurodegeneration remains elusive.
Results: To understand the pathological consequences of this mutation, here we present a new Caenorhabditis
elegans model expressing the mutant A152TMAPT in neurons. While expression of full-length wild-type human tau
(Tauwt, 2N4R) in C. elegans neurons induces a progressive mild uncoordinated locomotion in a dose-dependent
manner, mutant tau (TauA152T, 2N4R) induces a severe paralysis accompanied by acute neuronal dysfunction.
Mutant TauA152T worms display morphological changes in neurons reminiscent of neuronal aging and a shortened
life-span. Moreover, mutant A152T overexpressing neurons show mislocalization of pre-synaptic proteins as well as
distorted mitochondrial distribution and trafficking. Strikingly, mutant tau-transgenic worms do not accumulate
insoluble tau aggregates, although soluble oligomeric tau was detected. In addition, the full-length A152T-tau
remains in a pathological conformation that accounts for its toxicity. Moreover, the N-terminal region of tau is not
toxic per se, despite the fact that it harbours the A152T mutation, but requires the C-terminal region including the
repeat domain to move into the neuronal processes in order to execute the pathology.
Conclusion: In summary, we show that the mutant TauA152T induces neuronal dysfunction, morphological
alterations in neurons akin to aging phenotype and reduced life-span independently of aggregation. This
comprehensive description of the pathology due to TauA152T opens up multiple possibilities to identify cellular
targets involved in the Tau-dependent pathology for a potential therapeutic intervention.
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Background
Neurodegenerative diseases are a leading cause of de-
mentia and pose a serious threat to our aging popula-
tion. Among them, tauopathies (including AD and
FTDP-17) characterized by the accumulation of highly
phosphorylated insoluble tau [1–3] are the most com-
mon. Tauopathies can be of two types [4]; sporadic and
familial. A small percentage of patients (1–5 %) develop
disease as a result of mutations in the tau gene (MAPT).
These mutations can have multifarious consequences;
they are capable of reducing the microtubule binding af-
finity of tau and therefore result in a partial loss of func-
tion of tau [5]. Moreover, these mutations are able to
increase the beta-propensity of tau, making it more
prone to aggregation. Consistent with this, the majority
of MAPT mutations studied so far are clustered in or
near the repeat domain of tau which is responsible for
aggregation [1]. However, a rare point mutation in tau
gene (A152T) was recently reported in patients suffering
from PSP, FTD, or AD [6–8]. This mutation is unique
since it lies far outside of the repeat domain in the N-
terminal proline-rich region which is thought to interact
with different signalling pathways due to its interactions
with proteins containing SH3-domains [9, 10].
The amino acid substitution A152T in tau has been
shown in vitro to be associated with a reduced microtubule
binding affinity and, an increase in formation of Tau oligo-
mers instead of insoluble PHFs [6]. Whether this amino
acid substitution has any bearing on the development of
disease remains uncertain, due to scarcity of in vivo data.
Therefore, to understand the pathological consequences of
the A152T mutation in the context of a whole organism,
we used the nematode C. elegans as a model. It offers sev-
eral advantages over other animal models. For example, it
has a transparent body with a simple nervous system,
which makes it possible to image the progression of path-
ology at the cellular and sub-cellular level. It has a short
life-span (2–3 weeks) and is genetically well characterized
and tractable. For these reasons, C. elegans has been exten-
sively used as a model of neurodegeneration [11–13] and
has provided invaluable insights into the nature of the path-
ology involved. Several key pathways and signalling mole-
cules are conserved between worms and mammals [14].
Two genes implicated in tau pathology (sut-1 and sut-2)
have been identified in a genetic screen using C. elegans
[15, 16], which point to effects involving the microtubule
and actin cytoskeleton. More recently, we demonstrated
the potential of using C. elegans as a tool for the screening
of neuroprotective compounds; in fact one of the com-
pounds (MB) that proved beneficial to this model [17] is
running in the 3rd phase of clinical trial [18]. All in all, stud-
ies of the C. elegans nervous system have greatly aided ef-
forts to analyze the causes of neurodegenerative diseases on
the path to developing an effective treatment.
To investigate the functional consequences of this muta-
tion in vivo, we generated pan-neuronal mutant A152T-
tau (htau40A152T, hereafter referred to TauAT) and wild-
type tau (htau40WT, or Tauwt) overexpressing nematodes.
We found that, while the expression of Tauwt led only to
mild pathology over time and in dose-dependent manner,
the mutant TauAT showed pronounced pathology from an
early age. The pathology induced by TauAT was dose-
independent, manifested as severe paralysis, defects in the
GABAergic motor neurons, accumulation of morpho-
logical abnormalities in touch neurons reminiscent of
neuronal aging and reduced life span. At the cellular level,
TauAT worms displayed altered distribution of major neur-
onal organelles (synaptic vesicles and mitochondria) and a
perturbed mitochondrial trafficking. The worms express-
ing TauAT showed the protein in a pathological state as
confirmed by staining with the conformation-dependent
MC1 antibody, whereas Tauwt worms showed only min-
imal staining. Furthermore, in mutant worms TauAT ap-
peared mostly as soluble higher molecular weight
oligomers, albeit they did not accumulate as insoluble ag-
gregates. We also demonstrated that although the muta-
tion site lies in the N-terminal half of TauAT, the C-
terminal half which engages with the microtubules is ne-
cessary for pathology.
Results
Expression of mutant TauAT leads to severe locomotor
defects
To examine the consequences of the Tau mutation
A152T in vivo, we generated transgenic worms express-
ing constitutively either the wild-type Tauwt or the TauAT
mutant form of human 2N4R Tau in neurons. The pan-
neuronal expression was achieved using the synaptobre-
vin promoter snb-1p (Fig. 1a). Multiple lines were ob-
tained after transgene integration. We first compared
the protein levels by subjecting the worm lysates from
each strain (3 day old adults) to western blotting using
K9JA pan-Tau antibody. Two lines from each set of
transgenes were selected for further analysis; worms
showing comparably lower expression levels (referred to
hereafter as Tauwt-lo or TauAT-lo, resp.) or higher ex-
pression levels (termed Tauwt-hi and TauAT-hi, resp.).
Total tau levels in Tauwt-lo and Tauwt-hi lines were com-
parable with their mutant counterparts TauAT-lo and
TauAT-hi, respectively (Fig. 1b, c). Immunostaining with
K9JA antibody showed that Tau transgenes were
expressed in the entire nervous system, notably in the
major ganglion nerve ring and the nerve cords (Fig. 1d,
Additional file 9). Non-transgenic animals did not show
any staining for human Tau (data not shown).
Worms expressing Tauwt exhibit motor defects with
mild uncoordinated (Unc) phenotype characterized by
sluggishness and a distorted sinusoidal locomotion
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relative to non-transgenic worms (Fig. 1e). However, in
worms expressing TauAT the severe Unc phenotype is
much more pronounced than in worms expressing
Tauwt. Most of the worms expressing mutant TauAT were
paralytic and were often seen in the coiled state, almost
completely unable to move (Fig. 1e). The extent of motor
dysfunction in worms expressing Tauwt correlated with
the protein expression levels, Tauwt-lo with lower tau
levels showed a milder phenotype (~30 thrashes/30 s)
than Tauwt-hi line (~20 thrashes/30 s) with higher tau
levels (Fig. 1f, also see Additional file 1: Movie S1 and





Fig. 1 Mutant human TauAT causes severe paralysis in C. elegans. a Bar diagram of Tau (2N4R, 441 residues, largest isoform in human CNS) with 2
inserts (N1, N2 near the N-terminus) and 4 repeats (R1-R4 in the C-terminal half) used to generate tau-transgenic lines. The point mutation A152T
lies outside of the repeat domain in the proline rich region. The pan-neuronal promoter (Psnb-1) drives the expression of human tau cDNA in the
C. elegans nervous system and the 3′UTR aids in tau expression. b Total worm lysates from synchronized day-3 old adults analyzed for Tau by
western blotting using pan-tau antibody K9JA. Two independently integrated strains expressing Tau at comparably low and high levels were
selected from each transgene: wild-type htau40 (Tauwt-lo and Tauwt-hi) and mutant htau40A152T (TauAT-lo and TauAT-hi). Tubulin serves as
internal control. c Quantification of total tau in wild-type Tau lines (Tauwt-lo and Tauwt-hi) and mutant Tau-A152T lines (TauAT-lo and TauAT-hi).
Error bars denote SEM. One-way ANOVA with Tukey’s test was applied for multiple comparisons (ns, non-significant, *P < 0.05, **P < 0.01).
d Immunochemistry of whole worms with pan-tau K9JA antibody shows tau staining in the nervous system. Top panels depict nerve ring
ganglion, bottom panels show ventral cord region. e Synchronized day-1 old adults were placed onto the centre of NGM plates freshly spotted
with E. coli OP-50 and photographed after 10 min. Both TauAT-lo and TauAT-hi worms show strong paralytic phenotype apparent by their coiled
body shape and lack of tracks on the E. coli lawn. The corresponding lines expressing wild-type human tau (Tauwt-lo and Tauwt-hi) possess a mild
uncoordinated phenotype and are able to crawl away from the point of origin. f Thrashing assay of synchronized day-1 old adults in liquid.
Control worms (non-tg control or worms expressing GFP in the pharynx as transformation marker only) display a high frequency of ~50 thrashes/
30s. Worms expressing Tauwt display a dose-dependent motor impairment with reduced thrashing frequency (~30/30s for Tauwt -lo, ~20/30s for
Tauwt -hi). Motor impairment is very severe in the worms expressing mutant TauAT (both -lo and -hi, ~2/30s). One-way ANOVA with Tukey’s test
was applied for multiple comparisons. Error bars denote SEM, n≥ 30. (ns., non-significant, *P < 0.05, **P < 0.01, ***P < 0.001)
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toxicity did not correlate with protein expression levels;
the Unc phenotype was equally severe in TauAT-lo and
TauAT-hi worms (Fig. 1f, also see Additional file 3: Movie
S3 and Additional file 4: Movie S4). Tau transgenes (Tauwt
and TauAT) when expressed as extrachromosomal arrays
showed comparable Tau levels as detected by western blot
using K9JA antibody (see Additional file 10), and yielded
similar phenotypes as the integrated lines (see Additional
file 10), ruling out any effects due to unwanted back-
ground mutations during integration.
Mutant TauAT leads to pronounced GABAergic
neurodegeneration, while Tauwt causes mild degeneration
only at higher levels
Normal sinusoidal locomotion in C. elegans is made pos-
sible by coordinated activity of reciprocal motor circuits
comprised of inhibitory GABAergic and excitatory cholin-
ergic neurons located along the body wall [19], and any
interruption in the networking produces a defective loco-
motion (uncoordinated). To evaluate the possibility that
the locomotion phenotype in tau-transgenic worms is due
to a defective motor nervous system, the integrity of
GABAergic motor system was monitored. Animals were
analyzed for axonal gaps in the ventral and dorsal cords
by crossing them into the juIs73:[Punc-25::gfp]III trans-
gene [20] that allows visualization of GABAergic motor
neurons by expression of GFP (Fig. 2b). GABAergic motor
neurons in both the worm strains expressing TauAT
(TauAT-lo and TauAT-hi) were severely abnormal with fre-
quent gaps in ventral and dorsal cords, often showing
stretches of nerve cords missing (Fig. 2e, F and see Add-
itional file 10, Additional file 11), consistent with the extent
of motor dysfunction shown by these worms (see Fig. 1e).
On the other hand, GABAergic motor neurons in worms
expressing Tauwt were slightly affected (lesser gaps) when
compared to worms expressing TauAT (Fig. 2c, d; Table 1).
However, when compared to non-tg reporter strain (juIs73),
Tauwt worms did exhibit a significant number of gaps
(Table 1). Consistent with the motor deficits, the extent of
neuronal damage seen in worms expressing Tauwt
depended on the level of protein expression, with Tauwt-hi
accumulating more damage than Tauwt-lo (Table 1).
Since the lines TauAT-lo and TauAT-hi did not differ
much in their phenotypes, from hereon we decided to
compare the two wild-type tau lines (Tauwt-lo and
Tauwt-hi, which differ depending on Tau levels) with the
mutant line with lower tau expression (TauAT-lo), unless
otherwise mentioned.
Mutant TauAT induces hallmarks of aging neurons and
shortens the life-span
The above microscopical observations of the GABAergic
neurons clearly showed that their processes are degener-
ating, consistent with the locomotor defects seen in
Tau-tg worms. As neuronal restructuring and synaptic
disintegration is one of the hallmarks of aging nervous
system [21, 22], we asked whether the TauAT variant initi-
ates such changes which could be interpreted as indication
of premature aging of the nervous system. Mechanosen-
sory neurons (touch neurons) offer an excellent model to
study changes associated with neuronal aging in C. ele-
gans. These neurons undergo morphological changes such
as irregular outgrowths from somata, extra neurites, and
bending of main neuronal processes that become exagger-
ated with age [23, 24]. We therefore generated Tau-tg
worms carrying zdIs5:[Pmec-4::GFP + lin-15(+)] transgene
that specifically express GFP in the six mechanosensory
neurons. We observed significant morphological alter-
ations of these neurons early in adulthood (day 1) of
TauAT worms, changes that have been associated with
aging in previous studies [23, 24]. We focussed on ALM
neurons (anterior lateral microtubule cells) located in the
anterior body region. ALM neuronal processes in TauAT
worms appeared wavy, in contrast to the straight pro-
cesses seen in non-tg (zdIs5) and Tauwt worms (both
Tauwt-lo and Tauwt-hi), and new outgrowths started eman-
ating from the somata already at day 1 (Fig. 3b, panel
day1). A higher percentage of TauAT-lo worms (~70 %)
showed these morphological abnormalities at day 1 com-
pared to non-tg (~12 %), Tauwt-lo (~20 %) and Tauwt-hi
worms (~23 %) (Fig. 3d). Furthermore, nearly 10 % of
non-tg animals showed a single posterior projecting neur-
ite emanating from ALM somata at day 1 consistent with
the earlier studies [24], whereas the incidence of such
neurites in TauAT-lo ALM neurons was found in almost
all the animals. By contrast, worms expressing Tauwt
(Tauwt-lo and Tauwt-hi) showed normal morphology
(Fig. 3b, panel day1). However, the number of animals
showing ALM neurons with a single posterior projecting
neurite was higher in Tauwt worms (~30 %) compared to
non-tg animals (~12 %). The severity of these morpho-
logical abnormalities further increased with age, new out-
growths that started emanating from ALM somata of day-
1 old TauAT-lo worms had extended to a considerable
length and occasionally underwent branching. Further-
more, the single posterior projecting neurite also showed
new outgrowths at multiple sites by day 3 of adulthood (ex-
ample in Fig. 3c, panel day 3). By this age, about 30 % of
the worms expressing Tauwt showed morphological abnor-
malities similar to day-1 TauAT worms (Fig. 3d).
A similar trend was seen in PLM neurons (posterior lat-
eral microtubule cells), but the degree of restructuring (ac-
cumulated damage) was less extensive (Tauwt-lo: ~10 %,
Tauwt-hi ~20 % and TauAT-lo: ~60 % at day 1). This is con-
sistent with earlier reports whereby neuronal populations
were found to differ in terms of vulnerability during aging
[24]. Overall our data suggests that the appearance of
these morphological changes in neurons that accompany
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the aging of C. elegans occur early in TauAT worms com-
pared to Tauwt and non-tg. As previous studies have
underlined the role nervous system plays in modulating
the lifespan in C. elegans [25–29], one would expect a re-
duced life-span in the worms expressing TauAT. Ultim-
ately, we assessed the survival of Tau-tg animals (Fig. 3e):
Tauwt expression resulted in a shorter life-span (~45 %
shorter vs. non-tg animals), but mutant TauAT expression
decreased the life-span even much more (~65 % shorter
vs. non-tg, ~25 % shorter vs. Tauwt (-lo or -hi) (Table 2).
Mutant TauAT worms display perturbed distribution of
major neuronal organelles and defective presynaptic
neurotransmission
Since TauAT worms showed early morphological alter-
ations mimicking aging neuronal phenotypes, we sought
to investigate the status of the neuronal transport
Table 1 Quantification of GABAergic neuronal damage in day-1
old Tau-tg worms
Strain VC gaps DC gaps N
non-tg 0.4 ± 0.08 0.2 ± 0.14 25
Tauwt-lo 1.4 ± 0.17* 1.1 ± 0.09 20
Tauwt-hi 2.6 ± 0.34** 1.7 ± 0.71* 18
TauAT-lo 5.8 ± 1.61*** 6.1 ± 1.14*** 24
TauAT-hi 6.1 ± 0.98*** 5.5 ± 1.4*** 25
Morphological abnormalities in GABAergic inhibitory neurons apparent as
gaps in the dorsal cord (DC gaps) and ventral nerve cord (VC gaps) were
assessed with the Punc-25::gfp reporter. N denotes the total number of
animals scored per strain. Non-tg worms with Punc-25::gfp reporter serve as
controls. P values for statistical significance are derived using ANOVA







Fig. 2 Mutant TauAT leads to substantial damage in GABAergic motor neurons. Punc-25::gfp reporter that labels GABAergic inhibitory neurons with
GFP, was crossed with respective tau-transgenic worms to visualize these neurons. a Cartoon depicting the GABAergic inhibitory motor system in an
adult worm. b-f depict representative maximum intensity projections (MIP) of day-1 old adults of the transgenes. For whole worm MIPs, see Additional
file 11. Abnormalities seen as gaps in the GABAergic inhibitory neurons are highlighted by arrowheads. GABAergic neurons show normal connectivity
in non-tg reporter worms, both dorsal and ventral nerve cords are intact (b). Expression of Tauwt produces dose dependent abnormalities in GABAergic
neurons, with Tauwt -hi neurons (d) accumulating more damage than Tauwt -lo (c). However, mutant TauAT expression leads to severe abnormalities in
the form of gaps in the dorsal and ventral nerve cords, both TauAT-lo (e) and TauAT-hi (f). One of the striking features of mutant TauAT worms is the
absence of stretches of dorsal cord (bracketed areas), not found in non-tg worms or Tauwt worms. See Table 1 for detailed quantitative analysis
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machinery in the transgenic animals. We checked the
distribution of major neuronal cargoes in neurons,
which represents an indirect readout for the transport
machinery [30]. We first looked at RAB-3, a synaptic
vesicle associated Rab GTPase [31], using the the
transgene vdEx262:[Pmec-4::mCherry::rab-3;Punc122::gfp]
[32] that expresses mCherry fused to RAB-3 in mechano-
sensory neurons. Worms expressing Tauwt (Tauwt-lo or
Tauwt-hi) showed uniform distribution of RAB-3 along
axons similar to non-tg (vdEx262) animals at day 1
(Fig. 4b). In contrast, TauAT-lo worms showed accumula-
tion of RAB-3 in the distal axon and less RAB-3 puncta in
the mid-neuron. Furthermore, posterior minor neurites
which are usually devoid of RAB-3 (as seen in non-tg
worms, Tauwt -lo and Tauwt -hi worms), were abnormally
filled with RAB-3 clusters in TauAT-lo worms (Fig. 4b). In
older animals, the RAB-3 marker started mislocalizing
even in Tauwt worms such that at day 3, RAB-3 was
present in minor neurites, similar to day-1 old TauAT-lo
worms (Additional file 12). We quantified the percentage




Fig. 3 Mutant TauAT induces morphological changes in mechanosensory neurons early in the adulthood and reduces life-span. a Cartoon
depicting a normal healthy neuron and a neuron showing morphological changes associated with aging like sprouting, non-specific branching and
bending. b Mutant TauAT worms show neuronal abnormalities reminiscent of aging neurons. Pmec-4::gfp reporter that expresses GFP in mechanosensory
neurons, was crossed into tau-transgenic worms and neurons visualized for morphological abnormalities at the days indicated. Note the soma outgrowth
(yellow arrowhead) and bending of neuronal process (white arrow) in TauAT-lo at day 1. At this age, Tauwt (both -lo and -hi) show normal morphology and
do not differ from non-tg. Only the incidence of an infrequent posterior extension (white arrow heads) increases in the Tauwt worms (to 30 % compared
with 10 % in non-tg at day 1), whereas in TauAT-lo this posterior extension occurs in almost 100 % of the animals. c The severity of the phenotype increases
with age. Soma outgrowths visible in TauAT-lo animals at day 1 grow and undergo further branching with age (yellow double arrowhead). The volume
marker GFP accumulates in beaded structures in the posterior extension in TauAT-lo worms and small outgrowths emanate from posterior extension (white
double arrowhead). These beaded structures could represent starting points of new branches, and were previously shown to be associated with
mitochondria [24]. d Quantification of animals with gross non-specific neuronal abnormalities (bends and branches) at two time points, day 1 and day 3.
Error bars denote mean ± SEM, n≥ 20. **P≤ 0.01, ***P≤ 0.001. Paired t-test with unequal variance was used for comparison. e Representative survival
curves of tau-transgenic animals, non-tg serves as control. Mantel-Cox log-rank test was performed to determine the statistical significance for the worm
life-span. (for P-values see Table 2)












non-tg 22 111/120 >10-4 >10-4
Tauwt-lo 12 87/120 >10-4 >10-4
Tauwt-hi 12 67/120 >10-4 >10-4
TauAT-lo 7 111/120 >10-4 >10-4 >10-4
TauAT-hi 6 110/120 >10-4 >10-4 >10-4
Pir et al. Molecular Neurodegeneration  (2016) 11:33 Page 6 of 21
the distal axon and the minor neurite at day 1 and day 3.
A higher percentage of TauAT-lo animals (~60 %) pre-
sented mislocalized mCherry::RAB-3 compared to non-tg
worms (~5 %), Tauwt-lo (~10 %) and Tauwt -hi (~15 %)
worms at day 1. All of these fractions increased substan-
tially with time, with TauAT-lo animals showing the most
advanced mislocalization of mCherry::RAB-3 puncta (see
Additional file 12 for an example).
We sought to clarify whether the mislocalization of
mCherry::RAB-3 is due to a disruption in the polarized
protein trafficking. To this end, PVD sensory neurons in
C. elegans represent suitable test cells because they pos-
sess distinct axonal-dendritic compartments, with highly
branched dendrites encircling the body, while the axon
protrudes to the ventral nerve cord and then grows an-
teriorly [33, 34] (see schematic in Fig. 5a). We generated
Tau-tg worms carrying kyIs445:Is:[Pdes-2::mCher-
ry::RAB-3;des-2::SAD-1::GFP;odr-1::DsRED] transgene
that expresses mCherry fused to RAB-3 in PVD sensory
neurons [35]. mCherry::RAB-3 puncta were barely de-
tectable in the PVD dendrites of Tauwt (-lo or -hi) ani-
mals, similar to non-tg (kyIs445) worms, with only faint
signals detectable in Tauwt-hi at day 1 and increasing
with age (Fig. 5b, c). Contrary to this, in TauAT worms
mCherry::RAB-3 was already mislocalized to the entire
PVD dendritic compartment at day 1 (Fig. 5b, panel
day1 dendritic). At the same time, the axons of TauAT
worms showed less dense puncta (Fig. 5b, panel day1
axonal). Altered synaptic vesicle distribution could mean
that the axonal compartments are compromised in
TauAT worms, implying that there might be a neuro-
transmission failure at the synapses.
To confirm this, we turned to a complementary ap-
proach by using chemicals aldicarb and levamisole that
interfere with normal neurotransmission [36]. Aldicarb
causes paralysis due to hypercontraction of muscles by
inhibiting acetylcholine esterase. Levamisole has a similar
effect as an acetylcholine receptor agonist. Normal worms
with intact pre- and post-synaptic compartments are sen-
sitive to both chemicals. Worms with either a pre- or a
post-synaptic defect show resistance to aldicarb, whereas
only worms with a post-synaptic defect show resistance to
levamisole. Tauwt-lo and non-tg (N2) worms were sensi-
tive to aldicarb, indicating a normal release of acetylcho-
line at synapses. However, Tauwt-hi, TauAT-lo and TauAT-
hi showed a mild resistance to aldicarb (Fig. 5d). On the
other hand, all the tau-transgenic lines were equally sensi-
tive to levamisole and did not differ from non-tg (Fig. 5e).
Thus these experiments argue that the pre-synaptic com-
partments are compromised in tau-tg worms.
Next we analyzed the distribution of another intra-
cellular organelle, mitochondria. The wyEx2709
[Pitr-1::TOM-201-54aa::yfp] is a transgene that expresses























Fig. 4 Mutant TauAT worms show aberrant localization of presynaptic components in mechanosensory neurons. a Schematic representation of
presynaptic cargo distribution in a normal healthy mechanosensory neuron and a neuron in an aged animal. b Day-1 old worms visualized
after crossing them into vdEx262:[Pmec-4::mCherry::rab-3] transgene that expresses mCherry fused to synaptic vesicle associated RAB-3 in
mechanosensory neurons. Tauwt-lo and Tauwt-hi show a similar distribution as non-tg reporter strain. TauAT-lo worms show accumulation of
mCherry::RAB-3 in the end neuron (yellow arrowhead), cell body (CB, white arrowhead) and posterior neurite (white arrow). By contrast, the
mid-neuron of TauAT-lo shows less puncta (6 ± 3 measured per 40 μm length) than non-tg (15 ± 5) and Tauwt-lo (17 ± 6) worms. On day 3,
mislocalization of mCherry::RAB-3 worsens in TauAT-lo worms, whereas Tauwt-lo and Tauwt-hi start accumulating mCherry:RAB-3 puncta in the
distal axon and posterior neurite (see Additional file 12)




Fig. 5 Mutant TauAT worms show presynaptic protein mislocalization in dendrites of PVD neurons and neurotransmission defects. a Schematic
representation of a PVD neuron with normal localization of mCherry::RAB-3 (pre-synaptic marker, red dots) and a PVD neuron with altered
localization. The branched morphology represents the dendritic compartment; the unbranched ventral process is the axon. b Representative
images of dendrites and axons at day 1 and day 3 of the mentioned transgenes. In non-tg and Tauwt worms (-lo and -hi), mCherry::RAB-3 localizes
in the axonal compartment and is excluded from the dendrites in young adults (day 1). By contrast, TauAT-lo worms show mCherry::RAB-3 mislo-
calized to the dendrites (yellow arrowheads) and a reduced distribution in the axons. With age, Tauwt (-lo and -hi) also show slight mislocalization
to the dendritic compartments (yellow arrowheads). Yellow dotted areas correspond to the dendrite not visible in non-tg, Tauwt-lo and Tauwt-hi
worms at day1. c Quantification of the fractions of animals with mislocalized presynaptic mCherry::RAB-3 puncta in tau-transgenes at day 1 (d1)
and day 3 (d3). Non-tg worms serve as control. Error bars denote mean ± SEM, n ≥ 20. **P ≤ 0.01, ***P ≤ 0.001. Paired t-test with unequal variance
was used for comparison. d Time-dependent paralysis induced by aldicarb (acetylcholine esterase inhibitor). Data represents the percentage of
worms (mean ± SEM) still able to move on 1 mM aldicarb plates after being touched, as a function of time. Non-tg and Tauwt-lo worms are highly
sensitive (bottom curves, grey and olive). Tauwt-hi, TauAT-lo and TauAT-hi worms show some resistance (blue, ochre, green curves, resp.). Strongly
resistant lev-1 (AChR mutant carrying the e211 allele) and mildly resistant rab-3 (Ras GTPase mutant carrying the js49 allele) are used as additional
controls (black and red curve, resp). After applying two-way ANOVA with Bonferroni correction, P < 0.01 at time points 45 and 180 min, whereas
P < 0.001 at time points 90 and 135 min is obtained for Tauwt-hi, TauAT-lo and TauAT-hi against non-tg. n = 20 animals, three independent
repetitions. e Time-dependent paralysis induced by levamisole (acetylcholine receptor agonist). Data represents the percentage of worms (mean
± SEM) still able to move on 0.2 mM levamisole plates after being touched, as a function of time. All the four tau-lines were as sensitive to
levamisole as non-tg. Strongly resistant lev-1 (e211) is shown as an additional control. n = 20 animals, three independent repetitions
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The DA9 soma lies in the preanal ganglion; it has a well
defined dendrite extending anterioventrally and an axon
that crosses the body to reach the dorsal cord and
then runs anteriodorsally. Non-tg animals display a
typical distribution of labelled mitochondria (schematic
in Fig. 6a, [37]; such that the anteriodorsal region
(boxed area, ~90 μm, Fig. 6a) contains closely spaced
(~5–10 μm) mitochondria, as seen in the non-tg
reporter strain (wyEx2709) (Fig. 6b, panel non-tg). But
away from the anteriodorsal region towards the distal
end, the spacing between the mitochondrial particles
increases (~30–50 μm) (data not shown). We then vi-
sualized mitochondria in our tau-tg animals by crossing
them into wyEx2709. TauAT-lo worms presented a
smaller number of mitochondria in all the three classified











































































































Fig. 6 Mutant TauAT worms display abnormal distribution of mitochondria. a Schematic representation of DA9 motor neuron displaying a normal
and an abnormal patterning of mitochondria in different compartments (blue dots). b Day-1 old adult worms of the tau-transgenes (left panel)
visualized after crossing them into the wyEx2709 [Pitr-1::TOM-201-54aa::yfp] reporter that highlights YFP-tagged mitochondria in DA9 motor neurons.
Magnified images of the region corresponding to the proximal axon (boxed area in the schematic) are shown to visualize the faint mitochondrial
particles (yellow arrowheads). Mitochondrial particles in day-3 old adult worms of the transgenes (right panel). Areas in white marked by asterisk
shows body autofluorescence. c, d, and e Quantification of the average number of mitochondria in different regions of DA9 neurons designated
as proximal axon (boxed region), distal axon (away from boxed region) and dendrite. TauAT-lo animals exhibit fewer mitochondria than non-tg
and Tauwt worms in all the specified compartments of the neuron at day 1 and day 3. Error bars show mean ± SEM, n≥ 20. **P≤ 0.01,
***P ≤ 0.001. Paired t-test with unequal variance was used for comparison
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Tauwt-lo and Tauwt-hi at both the time points (day 1 and
day 3) (Fig. 6b). However, compared to non-tg animals,
Tauwt expression led to an increase in mitochondria in a
dose dependent manner. This effect was more pro-
nounced in the distal axon, where Tauwt-hi worms
showed ~1.7 fold increase in mitochondrial number com-
pared to Tauwt-lo (Fig. 6c, d, e). Collectively, these results
show that the mutant TauAT distorts the normal distribu-
tion of neuronal cargoes in C. elegans neurons.
Altered mitochondrial distribution in mutant TauAT
worms is due to a defective transport
Altered steady state distribution of major neuronal car-
goes (synaptic vesicles and mitochondria) in TauAT ani-
mals is likely due to impaired neuronal transport
machinery. To investigate the effect of TauAT, we per-
formed mitochondrial trafficking analysis by generating
Tau-tg worms carrying jsIs609 transgene [17] which ex-
presses GFP fused to a mitochondrial localization signal
(MLS) in mechanosensory neurons. In order to get an
insight into how the transport machinery is affected in
different parts of neurons, we chose two regions, one
close to the cell body (up to ~80 μm from the cell body)
and another in the mid region (120 μm away from the
cell body) (refer to Fig. 4a), and recorded mitochondrial
movements in a time frame of 2.5 min. The transport
behavior was quite different in TauAT-lo compared to
non-tg (jsIs609) and Tauwt animals. Non-tg and Tauwt
animals generally showed long-haul uninterrupted
movements (range 10–15 μm), whereas TauAT-lo
animals displayed short bidirectional movements
(<5 μm) (Fig. 7a, also see Additional file 5: Movie S5,
Additional file 6: Movie S6, Additional file 7: Movie S7
and Additional file 8: Movie S8). Quantification revealed
a drastic decrease in the number of events (~30 to 60 %
reduction) in TauAT-lo animals compared to non-tg and
Tauwt (-lo and -hi) animals at both time points. With
age, non-tg and Tauwt-lo worms showed a decrease in
the number of trafficking events, especially in the prox-
imal region (~30–35 % reduction), whereas Tauwt -hi
and TauAT-lo did not display a drastic change in the traf-
ficking events in either of the regions with age (Fig. 7b, c).
In conclusion, TauAT-lo worms showed a severe defect in
mitochondrial transport compared to non-tg and Tauwt
animals, which provides a plausible explanation for the al-
tered steady state distribution of neuronal cargoes in the
worms expressing mutant TauAT.
Mutant TauAT adopts a pathological conformation but
does not form insoluble aggregates
A common feature of neurodegenerative diseases is pro-
tein aggregation. There is an ongoing debate regarding
the nature of the toxic species, e.g. the relatively stable
insoluble aggregates which could obstruct the cellular
space, or soluble aggregates in the form of oligomers
[38–40]. To address this question for the case of the
TauAT mutant, we first biochemically extracted tau from
day-1 old worms [17]. Soluble fractions were completely
extracted first by using a salt buffer (RAB), which
removes most of the soluble cytoplasmic fraction, followed
a
b c
Fig. 7 Time-resolved imaging of mitochondria reveals deficits in the trafficking machinery of mutant TauAT animals. a Representative kymographs
showing the nature of particle movements in different worm lines. Mitochondria in non-tg, Tauwt-lo and Tauwt-hi worms show long range
movements (in the range 8–15 μm) compared to TauAT-lo where mitochondria exhibit short and oscillatory movements (<5 μm). Quantitation
of number of mitochondrial trafficking events in proximal (b) and mid region (c) of mechanosensory neuron in day 1 and day 3 adults. TauAT-lo animals
show significant reduction in mitochondrial trafficking compared to non-tg and Tauwt-lo both at day 1 and day 3. However, Tauwt showed dose
dependent decreasing trends of trafficking events in both the regions of the neuron. Error bars show mean ± SEM, n ≥ 10. **P ≤ 0.001. Paired
t-test with unequal variance was used for comparison
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by a detergent buffer (RIPA), which removes protein-
protein or protein-membrane complexes. The detergent
insoluble pellet was finally reextracted with urea buffer
(Urea). Neither Tauwt nor TauAT accumulated deter-
gent insoluble tau at day-1 (Additional file 13). Next
we extracted tau from mixed stage worms consisting
mostly of > 3 days old ones. Here we used CK10 line
which is transgenic for htauV337M (1N4R) and is
known to accumulate detergent insoluble tau with age
(mixed stage) as a positive control [41]. The CK10 line
but not Tauwt or TauAT showed tau in the detergent in-
soluble fraction (Fig. 8a), although there was an in-
crease in the detergent soluble Tau fraction in Tauwt
and TauAT with age compared to the day-1 old adults
(see Additional file 13 for comparison).
To confirm our results, we generated another line ex-
pressing a Tau chimaera with two additional proline sub-
stitutions in the hexapeptide motifs (I277P and I308P),
besides the A152T mutation (termed TauAT+PP) (Fig. 8b).
The proline substitutions make this Tau chimaera inher-
ently incapable of forming detergent insoluble Tau fila-
ments because they block the amyloidogenic β-structure
[42]. We then compared the protein levels in the worms
carrying Tauwt, TauAT or TauAT+PP transgenes as extra-
chromosomal arrays at day 1, all of which showed com-









Fig. 8 (See legend on next page.)
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expectations, TauAT+PP resulted to be equally toxic and
the TauAT+PP worms were as paralytic as single mutant
TauAT worms (Fig. 8d,e). This argues that the toxicity
does not depend on the formation of β-structure and in-
cipient aggregation, in contrast to the pro-aggregant mu-
tation ΔK280 described earlier [17, 43].
Before the accumulation of insoluble aggregates as
tangles, Tau is known to undergo a change towards a
pathological conformation which accompanies
oligomerization during the pre-tangle state and can be
recognized by antibodies Alz-50 or MC-1 [44]. Using
MC-1 staining, we confirmed pathological conformation
and observed an extensive staining of nerve ring gan-
glion and nerve cords in TauAT-lo worms. By contrast,
Tauwt (-lo and -hi) worms showed only minimal staining
(Fig. 8f ) and non-tg worms showed no staining (data not
shown). Since it was reported previously that TauAT mu-
tant tau has a higher tendency to form oligomers in vitro
[6], we wanted to test if such oligomeric species also
exist in TauAT worms. To detect oligomers, we applied
native PAGE to analyze total lysate extracted from the
mixed stage worms in buffer C (see Methods) using
K9JA antibody. Lysate from Tauwt-lo showed protein ac-
cumulated in two bands (~170 KDa and >250 KDa
marked by asterisk in Fig. 8g). By contrast, the lysate
from TauAT-lo showed in addition a higher band (Fig. 8g,
black arrowhead) at the top of the gel and a smear in
the range of 72- 95 KDa (Fig. 8g, line), meaning that
TauAT worms accumulate a broad range of higher mo-
lecular weight tau species compared to Tauwt worms.
Lysate from non-tg worms on the other hand did not
show any reaction to K9JA antibody. We conclude that
the mutation A152T favors a pathological conformation
which might promote oligomerization.
The toxicity of mutant TauAT is not prevented by anti-
aggregation compounds
The conclusion that the toxicity of A152T mutation oc-
curred independently of the β-propensity of the repeat
domain was corroborated by treatment of TauAT-lo
worms with inhibitors of Tau aggregation (Rhodanine
compound bb14 and PTH compound BSc3094), that
were competent to ameliorate the phenotype of a worm
model based on tau aggregation [17]. The TauAT-lo
worms were treated with varying concentrations of com-
pounds in liquid culture for three days, starting from the
L1 larval stage. However, the compounds failed to im-
prove the paralytic phenotype of the TauAT-lo worms
(Fig. 8h). This implies that the principle behind the patho-
logical features observed in TauAT worms is perhaps dif-
ferent from that of the conventional Tau-aggregation.
The C-terminal half of Tau including the repeat domain is
necessary for the toxicity of human tau in C. elegans
neurons
The repeat domain of tau in the C-terminal domain har-
bors the primary physiological and pathological func-
tions of tau, stabilization of microtubules and formation
of aggregates in disease [45, 46]. Much less is known
about the functions of the N-terminal domain; but it is
known to interact with motor proteins and signalling
proteins [9, 47–49]. Additionally, the pathological con-
formation adopted by tau is achieved as a result of intra-
molecular folding of C-terminal against the N-terminal
(See figure on previous page.)
Fig. 8 Mutant TauAT does not aggregate, adopts a pathological conformation and anti-aggregation compounds do not rescue the paralysis. a Sequential
extraction of tau from aged animals (mixed stage consisting worms of mostly > 3 days old). CK10 line transgenic for htauV337M (1N4R) accumulates
detergent insoluble tau (insoluble aggregated tau); while no insoluble tau is detected in Tauwt or TauAT lines. 2N4R-tau (single arrow) in Tauwt and TauAT
lines migrates slower than the 1N4R-tau (double arrow) in CK10 worms. With age, more Tau accumulates in the detergent soluble fraction (representing
Tau bound to membranous structures) (see also Additional file 13A for day-1 old animals). b Bar diagram of anti-aggregant Tau construct TauAT+PP with
A152T mutation plus two additional proline substitutions in the hexapeptide motifs (htau40A152TI277PI308P). c 30 day-1 adult animals from non-tg, Ex[Tauwt],
Ex[TauAT] and its anti-aggregant variant Ex[TauAT+PP] after lysis in 1 x sample buffer, then subjected to 10 % PAGE and subsequent western blot analysis
using K9JA-pan-tau antibody. Ex[Tauwt], Ex[TauAT] and its anti-aggregant variant Ex[TauAT+PP] carrying the respective Tau transgenes as extrachromosomal
arrays (Ex) show comparable levels of Tau expression. Tubulin serves as loading control. d Micrographs of the worms. The anti-aggregant variant of mutant
TauAT (TauAT+PP) is equally toxic and produces a similar paralytic phenotype as the single mutant TauAT. Note the absence of tracks and coiled body in
Ex[TauAT+PP] similar to Ex[TauAT]. e Mean thrashing assay of day-1 old adult animals carrying Tauwt, TauAT or its anti-aggregant variant (TauAT+PP) transgenes
as extrachromosomal arrays. Ex[TauAT+PP] shows less thrashes than the non-tg (~5 % of non-tg) or Ex[Tauwt] worms (~9 % of Tauwt worms). But there is no
difference between the Ex[TauAT] and its anti-aggregant variant Ex[TauAT+PP], indicating that the toxicity does not depend on amyloidogenic aggregation.
Non-tg strain serves as control. Error bars denote SEM, n≥ 30. ***P < 0.001, ns., not significant. One-way ANOVA with Tukey’s test applied for multiple
comparisons. f Immunostaining of day-1 old Tauwt-lo, Tauwt-hi and TauAT-lo with conformation-specific antibody MC1. Tau in TauAT-lo worms adopts a
pathological state as seen by dense staining in the nerve ring and ventral cord. White arrows show stained neuronal processes either in the nerve ring or
ventral cord region. Tauwt (-lo and -hi) show only mild staining occasionally. g Worm extracts prepared from mixed stage adults in buffer C, resolved by
native PAGE and immunoblotted with K9JA show Tau enriched in soluble high molecular weight complexes in TauAT worm extracts. In addition to two
bands common to both Tauwt-lo and TauAT-lo lysates (~170 KDa and >250 KDa marked by asterisks), a smear in the range of 72-95 KDa corresponding to
lower oligomeric species and a higher band (> > 250 KDa, black arrowhead) can be seen in the TauAT-lo lysate. h Mean number of bends per 30 s of
TauAT-lo worms treated either with DMSO (solvent control) or with 50 or 100 μM concentrations each of known aggregation inhibitors of Tau (Rhodanine
compound bb14, PTH compound BSc3094 in DMSO). The lack of rescue indicates that the toxicity of TauAT is based on some mechanism distinct from
aggregation (for comparison see [17]). Error bars denote SEM. One-way ANOVA with Tukey’s test applied for multiple comparisons (ns., not significant)
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domains (discontiguous epitope MC-1, residues 5-15 +
312-322) [44]. Furthermore, mimicking the post-
translational modifications at epitopes of antibodies
AT8, AT100 and PHF-1 (upstream and downstream of
the repeats, resp.) leads to a change of the paperclip
folding of Tau that is known to consolidate the MC-1
epitope [50]. Since the A152T mutation lies in the N-
terminal projection domain of tau, we wondered if N-
terminal tau domains that lack a potential MC-1 epitope
would still produce a similar phenotype as the full-
length tau. We generated transgenic worms expressing
pan-neuronally the N-terminal tau (Nt-tau) chimaeras
(Met1-Leu243) with or without the mutation A152T
(Fig. 9a). Several lines carrying the N-terminal tau trans-
genes with or without the mutation (Ex[TauAT-Nt] and
Ex[Tauwt-Nt] respectively) as extrachromosomal arrays
were obtained by expressing the respective transgenes at
comparable levels. However, compared to worms
expressing full-length htau40 (Tauwt or TauAT) as extra-
chromosomal arrays (Ex[Tauwt] and Ex[TauAT] respect-
ively), worms expressing N-terminal fragments
(Ex[Tauwt-Nt] and Ex[TauAT-Nt]) showed much higher ex-
pression (5-10 fold) (Fig. 9b). In spite of these high
levels, the N-terminal tau fragments produced only a
slight reduction in mobility (thrashes) compared to non-
tg at day1 and day 5, and the difference became statisti-
cally insignificant at day 7 (Fig. 9c). These results are
consistent with earlier findings where an N-terminal
fragment of Tau expressed in mouse brain produced
phenotypically normal mice [48].
We then performed staining of worms expressing the
N-terminal tau fragments with the polyclonal antibody
SA4473 specific for the N-terminal half of tau. Nt-tau
fragments in these worms showed extensive staining ex-
clusively in somata and nuclei, but were largely excluded




Fig. 9 N-terminal tau fragments (wild-type or with A152T mutation) are not toxic to C. elegans neurons. a Bar diagram depicts the N-terminal
fragment of tau (amino acids Met1-Leu243) derived from full-length Tau. The pan-neuronal snb-1 promoter drives the expression of wild-type
N-t- or mutant N-t-fragment (Tauwt-Nt and TauAT-Nt respectively) in C. elegans neurons. b Blot showing the protein expression levels in worms
carrying N-terminal fragments or full-length tau transgenes as extrachromosomal arrays. 30 synchronized day-1 old adult worms from each
transgene (Ex[Tauwt-Nt], Ex[TauAT-Nt], Ex[Tauwt] and Ex[TauAT]) were lysed and subjected to western blot analysis using N-terminal Tau specific DA9
antibody (epitope at aa 100-130). Non-tg worms serve as control and tubulin as loading control. c Age-related comparison of rate of body
thrashing in liquid for days 1, 5 and 7 from the respective transgenic animals. In contrast to full-length tau (Tauwt or TauAT), expression of
N-terminal Tau fragments in C. elegans neurons (Tauwt-Nt or TauAT-Nt) cause only slight reductions (~10-13 %) in thrashing at day 1 and day 5. The
data points represent the mean (±SEM) thrashing rate and time point, n≥ 30. Two-way ANOVA followed by Bonferroni correction was used for
multiple comparisons. d Immunostaining of animals expressing either wild-type- or mutant-N-t tau fragments at different time points with
N-terminal tau-specific antibody SA4473. Top panels depict nerve ring ganglion while the bottom panels show nerve cords. N-terminal Tau
fragments show localization restricted to cell bodies and nuclei (white arrows), as nerve processes are largely invisible, in contrast to the situation
with full-length Tau (see Fig. 1c)
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show that N-terminal tau fragments which are unable to
move into the neuronal processes are not toxic to C. ele-
gans neurons. Thus a mild uncoordinated phenotype
due to Tauwt and a strong paralytic phenotype due to
TauAT could both be abolished by preventing the Tau
chimaeras to move into the neuronal processes. In con-
clusion, a severe toxicity occurs only when both condi-
tions are met; (a) presence in neuronal processes, (b)
A152T mutation. Therefore, we speculate that it might
be the ability of full-length tau to move into different
neuronal processes owing to its C-terminal half that
makes it toxic and the A152T mutation further aggra-
vates the problem, whereas restricting its localization to
the cell body by abolishing the C-terminal half renders it
non-toxic, even in the mutant form. Table 3 sums up
the data on the effect of various Tau variants when
expressed pan-neuronally in C. elegans.
Discussion
In this study we used a C.elegans model to examine the
toxicity of a rare mutation in the MAPT gene
(A152TMAPT) that was recently discovered as a risk
factor for frontotemporal dementia spectrum disorders
(FTD, PSP, CBD, AD, and others) [51]. Considering that
most Tau mutations lie in or near the repeat domain
and thus affect Tau-microtubule binding and Tau aggre-
gation, the A152T mutation is unusual in that it lies in
the proline-rich region far upstream of the repeat do-
main [7, 8], with only weak effects on Tau aggregation
[6]. This poses the question of an alternative mechanism
of toxicity. Over the years, several functions have been
assigned to the N-terminal domain of tau which do not
coincide with the functions of the repeat domain [9]. Ex-
amples of interactors with the N-terminal domain are
p150/Dynactin [47, 52], or signalling kinases containing
SH3 domains [48, 49, 53], which point to functions dis-
tinct from microtubule stabilization.
We found that elevation of wild-type human Tau
(Tauwt) in C. elegans neurons is already mildly toxic and
can induce late-onset pathology in a dose-dependent
manner, consistent with results from mouse models of
AD [54]. However, mutant TauAT at similar levels in-
duces a much more pronounced pathology with an early
onset. These worms developed severe motor dysfunc-
tion, paralysis and neurodegeneration of GABAergic
neuronal processes (Figs. 1 and 2). Since we observed
neurodegeneration in motor neurons, a condition often
associated with old age in humans [55], we hypothesized
that TauAT could cause effects similar to those observed
in aging neurons. This can be tested on mechanosensory
neurons by well-defined parameters [24], and indeed the
neurons of TauAT worms showed early signs of morpho-
logical abnormalities such as bendings and extra out-
growths from neuronal processes and somata (Fig. 3b, c)
compared to non-tg and Tauwt worms. The severity of
these morphological abnormalities increased with age
(Fig. 3c). Moreover, these signs of early aging on the
level of TauAT-expressing neurons corresponded to a
drastic reduction in life-span of the animals as well
(Fig. 3e). Since mutations in genes that reduce the life-
span also cause early onset of age-dependent morpho-
logical abnormalities in neurons [23, 24, 56], it is safe to
speculate that the pathways that are involved in inducing
such age-dependent morphological abnormalities might
get activated early in TauAT worms. However, some al-
ternate pathways that induce similar morphological
changes in neurons independently of aging have also
been reported [23, 34].
What could be the reasons behind the neuronal dys-
function and age-related phenotypes in TauAT worms?
Tau interacts with microtubules, microtubules are the
tracks for intracellular transport, and defects in neuronal
transport machinery have been linked to neurodegenera-
tion. This led us to search for signs of transport defects
in the neurons of TauAT worms. This was done for the
cases of two major neuronal cargoes, namely synaptic
vesicle (carrying Rab-3 GTPase) and mitochondria [57].
The TauAT worms presented a perturbed distribution of
both of these cargoes. For example, mCherry::RAB-3
puncta accumulated in distal axons and in cell bodies
but were depleted in the mid region of mechanosensory
neurons (Fig. 4, Additional file 12), consistent with
Table 3 Summary of different Tau variant transformations in C. elegans neurons (Toxicity index: %age reduction in thrashes when
normalized to non-tg)
Strain Sub-cellular localization Phenotype (Unc) Toxicity index
non-tg Non 0
Full-length (2N4R) hTau40wt-lo Cell bodies and neuronal processes excluding nucleus Weak ~30
Full-length (2N4R) hTau40wt-hi Cell bodies and neuronal processes excluding nucleus Mild ~60
Full-length (2N4R) hTau40AT (lo/hi) Cell bodies and neuronal processes excluding nucleus Strong ~90
Full-length (2N4R) hTau40AT+PP Cell bodies and neuronal processes excluding nucleus Strong ~90
N-terminal hTauwt (Met1-Leu243) Cell bodies and neucleus excluding neuronal processes No obvious phenotype ~13
N-terminal hTauAT (Met1-Leu243) Cell bodies and neucleus excluding neuronal processes No obvious phenotype ~15
Transgenic lines based on different Tau constructs are compared to the non-transgenic control (N2) animals
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defective retrograde and anterograde transport [58–60].
Moreover, not only the transport but the integrity of the
neuronal compartments was compromised in mutant
TauAT worms as suggested by the mislocalization of
mCherry::RAB-3 in the dendritic compartments of po-
larized PVD neurons (Fig. 5b, c) [33, 35].
Polarized sorting of synaptic vesicles requires ankyrin
(UNC-44) driven anchoring of CRMP (UNC-33) into
axons, which in turn drives plus-end directed microtu-
bules extending into the axons and subsequent plus-end
directed axonal traffic by kinesin (UNC-104) [35]. The ob-
served missorting of synaptic vesicle associated RAB-3
into dendrites of TauAT worms could be caused by several
factors, e.g. more plus-end directed microtubules in den-
drites, or mislocalization of ankyrin (UNC-44) and subse-
quent localization of CRMP (UNC-33) into dendrites,
both of which are normally excluded from this compart-
ment. The resulting changes in the dendritic microtubular
network due to CRMP could then trigger kinesin (UNC-
104) dependent traffic into the dendrites. Future studies
should reveal if this phenomenon in TauAT worms is re-
lated to a direct interaction of tau with ankyrin (UNC-44)
or CRMP (UNC-33). In addition to the microtubular net-
work, tau is also known to interact and directly or indir-
ectly influence the dynamics of the actin cytoskeleton
[61], and this cross-talk with the microtubule- and actin-
cytoskeleton might play a critical role in tau-induced neu-
rodegeneration [62]. In line with these findings, two sup-
pressors (sut-1 and sut-2) have been identified in a genetic
screen using C. elegans [15, 16]. Although a direct inter-
action between tau and SUT-1 or SUT-2 is not known;
however, both of these proteins interact with proteins as-
sociated with either microtubule-based or actin-based
cytoskeletal systems.
A similar correlation was seen with mitochondrial par-
ticles tagged with YFP in DA9 motor neurons. Mutant
TauAT worms showed less mitochondrial particles in the
synaptic areas of DA9 axons. Time-resolved imaging re-
vealed that this perturbed mitochondrial distribution is
due to a decreased mitochondrial trafficking in TauAT
worms (Figs. 6 and 7). This perturbed distribution of
neuronal organelles is analogous to the previous C. ele-
gans kinesin/dynein double mutant studies which re-
ported an overall decrease in the number density of
synaptic vesicles along the axonal processes and accu-
mulation of very few vesicles in the end neurons. This
can be explained by the fact that both retrograde and
anterograde transport processes are affected in a kine-
sin/dynein double mutant. On the other hand, the ex-
pression of Tauwt generated a phenotype analogous to a
dynein mutant where a deficient retrograde transport
leads to the accumulation of synaptic vesicles along the
distal part of the axon [59, 60]. These transport deficits
might also explain the extensive neuronal restructuring
of the touch neurons in TauAT animals (Fig. 3). The fact
that most of these non-specific branches grew directly
from the cell bodies supports the view that mitochondria
accumulate in the cell bodies which may provide local
energy for new outgrowths. Occasionally these non-
specific branches in touch neurons of TauAT worms
underwent further branching, consistent with earlier
studies that attributed this phenomenon to ROS produc-
tion by static dysfunctional mitochondria [24]. Overtime,
even wild-type Tauwt worms started showing these phe-
notypes, albeit to a lesser extent.
It is worth noting that in certain assays, Tauwt and
TauAT worms did not differ much, possibly because a
threshold in these phenotypic assays is lower and even
the wild-type tau was able to cross that threshold, albeit
at higher levels. For instance, Tauwt at higher levels led
to pre-synaptic defects similar to TauAT at both lower
and higher levels (Fig. 5d, e). Similarly, there was no
change in the phosphorylation status of tau in both
Tauwt and TauAT worms (Additional file 14). This indi-
cates that there is no special preference for mutant tau
with regard to phosphorylation by C. elegans kinases and
further suggests that tau phosphorylation may not be a
cause for toxicity. In addition, neither Tauwt nor TauAT
worms accumulated insoluble tau (Fig. 8a).
Aggregation is usually considered a hallmark of
Tauopathies such as AD, PSP, or CBD, but there is also
persuasive evidence that the toxic species are not the fully
developed insoluble and aggregated forms of the protein
but earlier soluble oligomeric precursors [63–65]. We
therefore searched for assembly forms of TauAT in the
transgenic worms. The results showed that there are no
detectable insoluble aggregates (as judged by the usual
standard isolation procedures), but an increase in soluble
oligomeric forms. In this regard, the TauAT are distinct
from other cases where aggregation-prone Tau mutants
were expressed and accumulated in the insoluble fraction
in C. elegans neurons, e.g. mutants V337M or ΔK280 [17,
41]. The absence of insoluble aggregates was further con-
firmed in two ways: (i) by expressing an inherently
aggregation-incompetent Tau construct with two proline
substitutions in the hexapeptide motifs plus the A152T
mutation which yielded a similar phenotype as a tau con-
struct with the A152T mutation alone (Fig. 8 d, e); and (ii)
by treating the TauAT worms with known aggregation in-
hibitor compounds, which offered no relief (Fig. 8h), in
contrast to worms expressing pro-aggregant forms of Tau
[17]. These experiments argue that the toxic principle of
TauAT does not depend on aggregation. Important to
mention here is that another line expressing a full-length
htau40A152T chimaera with an additional V337M muta-
tion (Ex[TauAT+VM]) also gave a similar phenotype as the
Ex[TauAT] line expressing the single mutant tau chimaera
htau40A152T (Additional file 13C,D). Keeping in mind
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that the A152T mutation lies in a region important for scaf-
folding and signalling pathways, it further suggests that the
mutation leads to a toxic gain of function distinct from ab-
errant aggregation. Indeed, the TauAT worms showed
strong staining with antibody MC-1 (Fig. 8f), a characteris-
tic feature of pathological conformational changes [44].
Thus the situation is reminiscent of other neurodegenera-
tive conditions where soluble pre-aggregates are the pri-
mary culprits behind the toxicity [66–68]. In line with these
findings, tau in A152T worms was detected mostly
enriched in the soluble higher molecular weight species
(potential oligomers) by native PAGE (Fig. 8g). A growing
body of evidence suggests that a cell combats the decline of
proteostasis due to toxic gain of function of proteins by se-
questering soluble proteins into insoluble aggregates [69,
70]. The fact that TauAT worms have a short life-span
(Fig. 3e) might explain that there is not enough time to se-
quester and circumvent toxic effects caused by soluble dif-
fusible tau. It would be of interest to investigate whether an
increase of life-span, e.g. by suppressing insulin-signalling
[71], would allow them to drive these soluble tau species
into insoluble aggregates, and subsequently whether the
pathological consequences are alleviated.
One important finding of this study was that the
TauAT mutant does not induce pathology unless tau
moves into the neuronal processes. It appears that C.
elegans neurons can easily cope with a tau chimaera, ir-
respective of whether it is wild-type or a A152T mutant,
provided that its localization is restricted to the cell
body. The evidence is that when expressing wild-type or
A152T mutant N-terminal tau fragments without the re-
peat domain, their localization was restricted to cell
body (Fig. 9d). The explanation is that the fragments
cannot engage to the microtubule-based transport ma-
chinery since they lack the MT-binding domain [72].
Both these lines were almost as healthy as the non-tg
lines (Fig. 9c), even though the N-terminal fragments
were expressed at a 5–10 fold higher level than full-
length tau (Fig. 9b). Secondly, a full-length variant of
Tau with two additional proline substitutions in the hex-
apeptide motifs (TauAT+PP) which is incompetent for ag-
gregation, but otherwise is transported normally into cell
processes (Additional file 15), induces pathology to the
same extent as that of TauAT (Fig. 8e). This supports
earlier findings in mice showing that tau needs to move
out of the cell body in order to exert its toxic effects
[48]. In the light of the current interest in the cell-to-cell
spreading of Tau it would be interesting to know
whether the intercellular propagation of TauAT could
contribute to the toxicity. However, this issue cannot be
addressed in the current model, as mutant Tau is
expressed pan-neuronally.
Taken together, the detailed description of the path-
ology due to the TauAT mutation provided by the new
worm models opens up multiple possibilities to identify
cellular components involved in the Tau-dependent
pathology and might contribute to the development of
novel therapeutic interventions of tauopathies.
Conclusions
In this study, we present a new C. elegans model to under-
stand the pathological consequences of A152TMAPT mu-
tation, recently identified in patients diagnosed with
frontotemporal spectrum disorders, including PSP, FTD,
CBD, and AD. Using this model we found that, while the
wild-type human tau (Tauwt, 2N4R) overexpression in C.
elegans neurons induces a progressive mild locomotor de-
fects in a dose-dependent manner, mutant tau (TauA152T,
2N4R) induces a severe paralysis accompanied by acute
neuronal dysfunction. TauA152T worms show morpho-
logical alterations in neurons similar to what has been re-
ported in aging neurons and exhibit a reduced life-span.
TauA152T overexpressing neurons show mislocalization of
cellular organelles and disrupted mitochondrial trafficking.
Importantly, TauA152T remains in a pathological conform-
ation but does not accumulate as insoluble aggregates.
Moreover, the C-terminal domain of tau which engages
with the microtubules is necessary to induce pathology
despite the fact that the A152T mutation lies in the
N-terminal domain. Together these data show that the
mutant TauA152T overexpression in C. elegans neurons in-
duces pathology that is not dependent on aggregation.
Methods
Plasmid constructs
To generate A152T cDNA [6], we used site-directed mu-
tagenesis (Stratagene QuikChange reagents) to introduce
the point mutation A152T into htau40WT cDNA. The re-
spective cDNAs encoding wild-type htau40WT and mu-
tant htau40A152T were ligated into SalI and KpnI sites of
pPD49.26 vector between the snb-1 promoter and unc-54
3′-UTR (a generous gift from Dr. B.C. Kraemer, University
of Washington, Seattle). Two additional proline substitu-
tions were introduced into mutant htau40A152T in the
hexapeptide motifs (I277P and I308P, intended to break
beta-structure) [73]. The resulting cDNA was cloned into
SalI and KpnI sites of pPD49.26 as described above, yield-
ing Psnb-1::htau40A152T(I277P)(I308P). Similarly, another
Tau chimaera with A152T plus V337M mutation was gen-
erated as described above and cloned into SaII and KpnI
sites of pPD49.26, yielding Psnb-1::htau40A152TV337M.
As the A152T mutation lies outside the repeat region of
Tau in the N-terminal domain, we also generated worms
expressing only the N-terminal regions of tau, residues 1-
243. We cloned the first 243 amino acid region of wild-
type and mutant tau cDNA into the BamHI and KpnI sites
of pPD49.26 to generate the transgene constructs Psnb-1::N
′t-htauWTMet1-Leu243 and Psnb-1::N′t-htauA152TMet1-Leu243
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respectively. All plasmid constructs were confirmed by
DNA sequencing.
Generation of transgenic lines
Complex arrays were generated by injection of Tau
transgenes along with a coinjection marker (Pmyo-2::gfp
or Pmyo-2::mCherry, gift of Dr. R. Baumeister) into the
gonad of N2 (Bristol) at 75 ng/μl. Coinjection markers
were used at a concentration of 20 ng/μl and also served
as controls when injected alone at the same concentra-
tions. To generate the stable lines, the transgenes were
integrated by exposing the animals to 300 J/m2 UV dose
[74]. Multiple stable transgenic lines were isolated, and
before proceeding further, the transgenic lines were
backcrossed to N2 wild-type at least five times to elimin-
ate any background mutations.
C. elegans maintenance and crosses were performed ac-
cording to the standard methods [75]. Worms were cul-
tured at 20 °C unless otherwise specified. N2 Bristol was
used as the wild-type C. elegans. The following transgenic
strains were used: PIR1: pirEx1[Psnb-1::htau40WT;Pmyo-
2::gfp], PIR2: pirEx2[Psnb-1::htau40A152T;Pmyo-2::gfp],





1::N′t-tauWT Met1-Leu243;Pmyo-2::mCherry], PIR9: pir-
Ex9[Psnb-1::N′t-tauA152T Met 1-Leu243;Pmyo-2::mCherry],
CZ1197: juIs73[Punc-25::gfp]III (gift of Dr. E. Lundquist),
PIR10: pirIs3;juIs73, PIR11: pirIs4;juIs73, PIR12: pirIs5;-
juIs73, PIR13: pirIs6;juIs73, zdIs5:[Pmec-4::GFP + lin-15(+)],
PIR14: pirIs3;zdIs5, PIR15: pirIs4;zdIs5, PIR16: pirIs5;zdIs5,
vdEx262:[Pmec-4::mCherry::rab-3;Punc122::gfp] (gift of Dr.
M. Hilliard), PIR17: pirIs3;vdEx262, PIR18: pirIs4;vdEx262,
PIR19: pirIs5;vdEx262, wyEx2709: [Pitr-1::TOM-201-
54aa::yfp;Podr-1::gfp] (gift of Dr. K. Shen), PIR20: pirIs3;-
wyEx2709, PIR21: pirIs4;wyEx2709, PIR22: pirIs5;wyEx2709,
jsIs609:Is:[Pmec-4::MLS::gfp] (gift of Dr. Nonet M), PIR23:
pirIs3; jsIs609, PIR24: pirIs4; jsIs609, PIR25: pirIs5;jsIs609,
kyIs445:Is:[Pdes-2::mCherry::RAB-3;des-2::SAD-1::GFP;odr-
1::DsRED] (gift of Dr. C.I. Bargmann), PIR26: pirIs3;kyIs445,
PIR27: pirIs4;kyIs445, PIR28: pirIs5;kyIs445, PIR29: pirEx29
[Psnb-1::htau40A152TV337M;Pmyo-2::mCherry], CK10:
bkIs10[Paex-3::htauV337M(1N4R);Pmyo-2::gfp], CB211: lev-
1(e211)IV and NM791: rab-3(js49)II.
Behavioral assays
For qualitative locomotor behavior, synchronized day-1
old adults were placed onto the center of NGM plates
freshly spotted with E. coli OP-50 and photographed
after 10 min. For thrash assays, synchronized animals
from each transgenic line were transferred into 20 μl of
M9 buffer (22 mM KH2PO4, 42 mM Na2HPO4, 86 mM
NaCl and 1 mM MgSO4) on a glass slide. After allowing
the animals to settle for 1 min, the frequency of body
bending was counted for 30 s [76].
Life span assay
A synchronous population of worms was obtained by
extracting eggs from gravid adults and incubated in M9
buffer overnight. Synchronised L1 larvae were collected
and allowed to grow until late L4 stage on regular NGM
plates seeded with E. coli OP50, and then transferred
onto OP50 seeded NGM plates containing 0.05 mg/ml
FUDR (5-fluoro-2-deoxyuridine) for the first two days to
inhibit growth of progeny. Thereafter, the worms were
grown again on regular OP50 seeded NGM plates and
scored every two days by tugging gently on the tail with
a platinum wire covered with bacteria. Worms that
failed to respond to touch were scored as dead. Graph-
Pad Prism software was used to perform the statistical
analysis.
Immunohistochemistry
Worms were permeabilized by freeze cracking after fix-
ation in 2 % paraformaldehyde solution as described previ-
ously [58]. Polyclonal rabbit pan-tau antibody (K9JA;
Dako A-0024) at a dilution of 1:5000 was used to detect
Tau. To monitor the conformational changes, we used the
pathological conformation-specific monoclonal mouse
antibody MC-1 [77]; (gift from Dr. P. Davies; 1:20). For
immunostaining of worms expressing N-terminal tau frag-
ments, rabbit polyclonal antibody SA4473 (Eurogentec;
1:300) was used. Respective secondary antibodies were
used at 1:350 dilutions. Stained animals were imaged at
63x using a Zeiss inverted epifluorescence microscope.
Imaging
GABAergic motor neurons were imaged by mounting
immobilized young adult animals in 50 mM sodium
azide (Sigma) on glass slides with 2 % agarose pads, and
imaged using a 20x or 40x objective on LSM700 (Zeiss).
To study the steady state distribution of synaptic vesi-
cles, worms were anesthetized in 50 mM sodium azide,
mounted on 2 % agarose pads, and neurons were imaged
at 63x with Zeiss inverted epifluorescence microscope.
For steady state imaging of mitochondrial marker Pitr-
1:TOM-201-54aa::yfp, we used Nikon microscope
equipped with Andor Spinning Disc Setup and EM-CCD
camera (Andor iXon 3). For live imaging of GFP tagged
mitochondria, worms of appropriate age (day-1 and day-
3 old adult) were anesthetized in 2-3 mM of levamisole
(Biomol) [58] and mounted on 2 % agarose pads. Time
lapse (3fps) images of mitochondria tagged with GFP in
mechanosensory neurons were acquired at 63x with a
Zeiss epifluorescence microscope equipped with a CCD
(Photometrics) camera. Images were acquired for
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constant time (t = 2.5 min) in two different regions of a
neuron, in the proximal part (axonal part adjacent to cell
body, ~60–80 μm) and middle part ~120 μm away from
cell body (refer to schematic in Fig. 4a). The number of
moving mitochondrial events was counted manually for
each genotype from the acquired movies. Representative
kymographs were generated using an ImageJ (NIH)
plug in.
Aldicarb and levamisole assays
To perform the aldicarb (acetylcholine esterase inhibi-
tor) and levamisole (acetylcholine receptor agonist) sen-
sitivity assays, day-1 old adult worms were transferred to
plates containing 1 mM aldicarb and 0.2 mM levamisole,
respectively and the time course of paralysis was assayed
as described previously [36, 78]. 20 animals per strain
were scored for paralysis and each experiment was re-
peated three times.
Pharmacological treatment
Chemical treatment was applied in liquid cultures as de-
scribed earlier [17]. Aggregation inhibitor compounds
bb14 (Rhodanine) or BSc3094 (PTH) were dissolved in
DMSO and added to the liquid culture at 50 and
100 μM concentrations.
Protein extraction
To extract total Tau protein, synchronized worms were
washed off NGM plates with water and the bacteria were
removed in the subsequent washing steps. The resulting
worm pellets (~100 mg) were resuspended in 1X protein
sample buffer containing 355 mM 2-mercaptoethanol
and boiled at 96 °C for 10 min. with continuous shaking
at 14,000 rpm. To determine the accumulation of insol-
uble tau aggregates, a slight modification of the previous
extraction protocol [17] was performed using buffers of
increasing stringency. Briefly, after removing the dead
animals and bacteria by flotation on a 30 % sucrose solu-
tion, worm pellets (~100 mg) were resuspended in twice
the amount (w/v) of high-salt RAB buffer [100 mM 2-
(N-morpholino) ethanesulfonic acid (MES), 1 mM
EGTA, 0.5 mM MgSO4, 20 mM NaF]. Worm pellets
were lysed completely by sonication (6 × 10 s, 10 s
break) on ice, and homogenates centrifuged at 40,000 g
for 40 min. The supernatant is the soluble RAB fraction.
RAB pellet was sonicated for 10 s in 1 M sucrose con-
taining RAB buffer and centrifuged for 20 min at
40,000 g, and the supernatant was discarded. The pellet
was extracted with RIPA buffer (150 mM NaCl, 1 %
Nonidet P-40, 0.5 % deoxycholate, 0.1 % SDS, 50 mM
Tris, pH 8.0) and centrifuged at 40,000 g for 20 min.
The supernatant constitutes the detergent soluble RIPA
fraction. The resulting pellet, after a brief washing with
RIPA buffer, was extracted with urea containing buffer
(UREA) [30 mM Tris, 7 M urea, 2 M thiourea, 4 %
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate), pH 8.5] and centrifuged at 13,000 g
for 15 min. The supernatant is the detergent insoluble
fraction.
For native PAGE, frozen worm pellets (~100 mg) were
resuspended in buffer C (20 mM Hepes, pH 7.9, 25 %
glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM DTT) and lysed by sonication (2 × 10 s, 10 s
break) on ice. After a brief centrifugation at 40,000 g for
5 min, the supernatants were analyzed on 4–12 % native
PAGE. The entire extraction procedures were carried
out on ice and centrifugation steps were at 4 °C. All
buffers contained Complete Protease Inhibitor Mixture
3× (Sigma-Aldrich P8340, Hamburg, Germany), 1 μM




Worm fractions (total or sequentially extracted - salt sol-
uble, detergent soluble or detergent insoluble) were mi-
grated in 10 % polyacrylamide gels, transferred to
nitrocellulose membranes (Immobilon) and immuno-
blotted. The following antibodies were used: DM1α-
tubulin (1:500; Sigma), K9JA (1:20,000; no. A0024;
Dako), AT8 (1:500; Thermo Scientific), PHF-1 (1:500; a
gift from Dr. P. Davies, Albert Einstein College, Bronx,
USA), 12E8 (1:500; Dr. P. Seubert, Elan Pharmaceuticals,
South San Francisco, USA), AT180 (1:500; Thermo Sci-
entific), AT100 (1:500; Thermo Scientific). For worms
expressing the N-terminal region of tau, antibody DA9
(raised against aa100-130, a gift from Dr. P. Davies) was
used at a dilution of 1:250. Peroxide-conjugated second-
ary antibodies and ECL solution (Thermo Scientific)
were used to visualize the blots. AIDA software (Raytest,
Germany) was used to perform densitometry.
Additional files
Additional file 1: Movie S1. Thrash assay performed with day-1 old
Tauwt-lo in M9 buffer. (MOV 3770 kb)
Additional file 2: Movie S2. Thrash assay performed with day-1 old
Tauwt-hi in M9 buffer. (MOV 6133 kb)
Additional file 3: Movie S3. Thrash assay performed with day-1 old
TauAT-lo in M9 buffer. (MOV 3920 kb)
Additional file 4: Movie S4. Thrash assay performed with day-1 old
TauAT-hi in M9 buffer. (MOV 3326 kb)
Additional file 5: Movie S5. Representative time lapse imaging
showing the movement of MLS::GFP labelled mitochondria in touch
neuron of a non-tg. The cell bodies in all the movies (not visible) are to
the left. White arrow marks anterogradely and pink retrogradely moving
mitochondria. Movies are displayed at 10x speed, scale bar: 5 μm. (MOV
432 kb)
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Additional file 6: Movie S6. Representative time lapse imaging
showing the movement of MLS::GFP labelled mitochondria in touch
neuron of a Tauwt-lo. (MOV 200 kb)
Additional file 7: Movie S7. Representative time lapse imaging
showing the movement of MLS::GFP labelled mitochondria in touch
neuron of a Tauwt-hi. (MOV 311 kb)
Additional file 8: Movie S8. Representative time lapse imaging
showing the movement of MLS::GFP labelled mitochondria in touch
neuron of a TauAT-lo. (MOV 255 kb)
Additional file 9: Pan-neuronal expression of human tau in C. elegans
by synaptobrevin promoter. Immunochemistry of Tauwt-hi and its mutant
counterpart TauAT-hi with pan-tau antibody K9JA showing Tau staining in
the nervous system. Panels on the left depict nerve ring ganglion, panels
on the right side show the ventral cord region. K9JA pan-tau antibody
does not stain wild-type non-tg worms (data not shown). (PDF 110 kb)
Additional file 10: Mutant TauAT transgene present as
extrachromosomal arrays induces severe locomotion defects in C. elegans.
(A) Worms carrying human tau-transgene arrays with A152T mutation
Ex[TauAT] show a severe motor impairment compared to the worms
carrying wild-type human tau-transgene arrays Ex[Tauwt]. Worms were
allowed to crawl for 10 min after placing them onto freshly spotted NGM
plates before photographing them. Ex[TauAT] worms are highly
uncoordinated and show a severe paralytic phenotype obvious by the
absence of tracks in the E. coli lawn and coiling behaviour. Arrows point
to the displacement from the origin. (B) 30 day-1 adult animals from
non-tg, Ex[Tauwt] and Ex[TauAT] lines were lysed and the lysate was
subjected to 10 % PAGE and subsequent western blot analysis using
K9JA-pan-tau antibody. Both Ex[Tauwt] and Ex[TauAT] carrying tau
transgenes as extrachromosomal arrays show comparable expression of
human tau. (C) Mean thrashing rate of day-1 old animals from strains
carrying Tauwt and TauAT transgenes as extrachromosomal arrays. Non-tg
wild-type strain serves as control. Error bars denote SEM, n≥ 30. *P < 0.05,
**P < 0.01, ***P < 0.001. One-way ANOVA with Tukey’s test was applied for
multiple comparisons. (D) Punc-25::gfp reporter staining GABAergic motor neu-
rons with GFP in non-tg and Tau-transgenic worms. Non-tg control worms
show intact ventral and dorsal nerve cords. Transgenic worms
carrying Tau-transgenes as extrachromosomal arrays show abnormal GABAer-
gic motor neurons. Worms expressing mutant htau40A152T (Ex[TauAT]) show
a severe loss of GABAergic neuronal system compared to the worms express-
ing wild-type tau (Ex[Tauwt]). Note the gaps (arrow heads) and absence of dor-
sal cord stretches (bracketed region) in Ex[TauAT] worms. (PDF 683 kb)
Additional file 11: Expression of mutant TauAT produces a substantial
damage in GABAergic motor neurons. Representative whole worm
maximum intensity projections (MIP) of the enlarged insets presented in
main Fig. 2. Punc-25::gfp reporter that labels GABAergic inhibitory neurons
with GFP, was crossed with respective tau-transgenic worms to visualize
these neurons. GABAergic neurons show normal connectivity in non-tg
worms, both dorsal and ventral nerve cords are intact (A). Expression of
Tauwt produced dose dependent abnormalities in GABAergic neurons,
with Tauwt -hi neurons (C) accumulating more damage than Tauwt -lo (B).
However, mutant TauAT expression led to severe abnormalities in the
form of gaps (arrowheads) in the dorsal and ventral nerve cords, in both
TauAT-lo (D) and TauAT-hi (E). Also see Table 1 for detailed quantitative
analysis. (PDF 276 kb)
Additional file 12: Aberrant localization of presynaptic components in
mechanosensory neurons worsens with age in mutant TauAT worms. (A)
Schematic representation of presynaptic cargo distribution in a normal healthy
mechanosensory neuron and in an aging neuron. (B) Presynaptic cargo
visualized in day-3 old worms after crossing them into vdEx262:[Pmec-4::mCher-
ry::rab-3] transgene, that expresses mCherry fused to synaptic vesicle associ-
ated RAB-3 in mechanosensory neurons. Mislocalization worsens in TauAT-lo,
whereas Tauwt-lo and Tauwt-hi start accumulating mCherry::RAB-3 puncta in
the distal axon (yellow arrowheads) and posterior neurite (white arrow). At day
3, the mid neuron of A152T worms becomes almost devoid of mCherry::RAB-
3 puncta. (PDF 186 kb)
Additional file 13: Mutant TauAT does not aggregate in C. elegans
neurons. (A) Sequential extraction reveals no insoluble tau in day-1 old
adults. Tau was sequentially extracted from day-1 old transgenic worms,
wild-type N2 (Bristol) worms served as control. Worms were lysed by son-
ication in high-salt buffer (RAB), centrifuged and supernatant collected as
salt soluble Tau fraction. Reextraction of salt insoluble pellet with
detergent buffer (RIPA) yielded detergent soluble Tau fraction. RIPA
insoluble pellet was finally dissolved in urea buffer (UREA) to extract any
insoluble fraction. Equal amount of protein was loaded and blotted using
K9JA pan-tau antibody. (B) Bar diagram of Tau construct TauAT+VM with
A152T mutation plus additional methionine substitution in the repeat
domain (V337M) (htau40A152TV337M). (C) 30 day-1 adult animals from
non-tg, Ex[TauAT] and the double mutant variant Ex[TauAT+VM] after lysis in 1
x sample buffer, then subjected to 10 % PAGE and subsequent western blot
analysis using K9JA-pan-tau antibody. Ex[TauAT] and Ex[TauAT+VM] carrying
the respective Tau transgenes as extrachromosomal arrays (Ex) show
comparable levels of Tau expression. Tubulin serves as loading control. (D)
Mean thrashing assay of day-1 old adult animals carrying TauAT or the
double mutant variant (TauAT+VM) transgenes as extrachromosomal arrays.
Ex[TauAT+VM] shows less thrashes than the non-tg (~5 % of non-tg). But
there is no difference between the single mutant variant Ex[TauAT] and the
double mutant variant Ex[TauAT+VM]. Non-tg strain serves as control. Error
bars denote SEM, n≥ 30, ns., not significant. One-way ANOVA with Tukey’s
test applied for multiple comparisons. (PDF 246 kb)
Additional file 14: Mutant TauAT does not differ in phosphorylation
status from wild-type Tau (Tauwt). Total Tau extracted from tau-tg worms
was examined for the phosphorylation status at the sites known to be
highly phosphorylated in the AD brain. Western blot analysis with
phosphorylation specific antibodies show that tau in all the strains is
highly phosphorylated at multiple sites examined (AT8 for pS199, pS202,
and pT205; PHF-1 for pS396 and pS404; 12E8 for pS262 and pS356; AT180
for pT231 and pS235, AT100 for pT212 and pS214). In addition to the
monomeric tau band (≈64 KDa, single arrow head), the phosphorylation
specific AT8 antibody also detects a band slightly higher than 64 KDa
band (double arrow head) and another band of ~120-KDa (triple arrow
head) specific only to tau-transgenic worms. BV P20 = highly
phosphorylated Tau of Baculovirus infected SF9 cells [79]. (PDF 355 kb)
Additional file 15: Mutant tau with anti-aggregant proline substitutions
(htau40A152T-I277P-I308P) localizes to the entire nervous system.
Immunohistochemistry of whole worms with pan-tau K9JA antibody
shows TauAT+PP localization in cell body and the neuronal processes.
Panels on the left side depict nerve ring ganglion and those on the right
side show ventral cord region. (PDF 174 kb)
Abbreviations
1N4R-Tau: 412 residues, 1 insert + 4 repeats; 2N4R-Tau: largest isoform of
human tau in brain (441 residues, 2 inserts + 4 repeats); ANOVA: analysis of
variance; MAPT: microtubule associated protein tau; MT: microtubules; non-
tg: non-transgenic; PHF: paired helical filaments; TauAT: human Tau (2N4R)
with mutation A152T; TauAT+PP: human Tau (2N4R) with proline substitutions
in the hexapeptide motifs; TauAT+VM: human Tau (2N4R) with mutation
A152T and V337M; TauAT-Nt: N-terminal fragment of mutant A152T tau;
Tauwt: human wild type Tau (2N4R); Tauwt-Nt: N-terminal fragment of wild-
type tau; Unc: uncoordinated locomotion.
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